查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1419143

流涎治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按藥物治療和最終用戶分類

Sialorrhea Treatment Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Medical Therapy and End User
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

依據「到 2030 年流涎治療市場預測 - 全球分析 - 按藥物治療和最終用戶分類」的最新研究，2022 年市場估值為 6.95 億美元，預計到 2030 年將達到 10.42 億美元；預計2022年至2030年CAGR為5.2%。

市場的成長歸因於神經退化性疾病的盛行率不斷增加以及流涎的各種治療方案的可用性。此外，不斷增加的研發（R＆D）和新藥批准可能會推動未來幾年流涎治療市場的成長。然而，與流涎治療相關的挑戰限制了市場的成長。

流涎的治療包括行為和生活方式諮詢、藥物、手術和放射。非藥物療法包括姿勢建議、控制吞嚥、控制咳嗽、飲食調整、飲食程序和行為改變。然而，這些保守措施可能不適用於患有隨著時間推移而惡化的神經系統問題的個體。許多用於治療流涎的藥物也具有抗膽鹼能特性，可用於控制流涎過多。阿米替林、丙環利定和利海索就是其中的一些。大多數藥物都有合併症（例如不適或睡眠困難）和唾液過多，這使得它們在某些情況下可能有幫助。因此，各種流涎治療方法的出現預計將在未來幾年推動市場成長。

然而，由於患者和醫療保健專業人員對該疾病的無知，慢性流涎的診斷和治療被延遲。預計這將成為阻礙慢性流涎治療市場擴張的主要障礙。此外，預計醫療保健專業人員（包括專家和基層醫療醫師）對持續性流涎作為一種單獨的疾病知之甚少。

該報告對流涎治療市場進行瞭如下細分：

流涎治療市場根據藥物治療和最終用戶分為兩部分。市場依醫療分為藥物治療、放射治療等。依最終使用者分類，流涎治療市場分為醫院、專科診所、家庭護理機構等。流涎治療市場依地理位置分為北美（美國、加拿大和墨西哥）、歐洲（法國、德國、義大利、英國、西班牙和歐洲其他地區）、亞太地區（澳洲、中國） 、日本、印度、韓國和亞太地區其他地區）、中東和非洲（沙烏地阿拉伯、阿拉伯聯合大公國、南非以及中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷） ，以及南美洲和中美洲的其他地區）

基於醫學治療的見解

依藥物治療，流涎治療市場分為藥物治療、放射治療等。 2022年，藥物治療領域佔據最大的市場。此外，預計該細分市場從 2022 年到 2030 年將創下最高CAGR。疫苗可提供針對特定傳染病的主動獲得性免疫力。在多項獨立臨床試驗中，苯托品、格隆溴銨、東莨菪鹼和肉毒桿菌毒素等藥物治療已被證明可有效控制流涎。藥物經由口服或腸胃外給藥。在解剖學外部觸診或超音波檢查的引導下將肉毒桿菌注射到唾液腺中。

基於最終用戶的見解

依最終使用者分類，流涎治療市場分為醫院、專科診所、家庭護理機構等。醫院細分市場在 2022 年佔據最大市場佔有率，預計 2022-2030 年CAGR最高。流涎的治療是在醫院透過適當的治療和運動療法進行的，並在經驗豐富的跨學科醫學專家（包括物理治療師和神經病學專家）的幫助下進行。

在準備有關流涎治療市場的報告時提到的一些主要的主要和次要來源包括世界衛生組織（WHO）和帕金森基金會等。

目錄

第 1 章：簡介

  • 研究範圍
  • 市場定義、假設與限制
  • 市場區隔

第 2 章：執行摘要

  • 重要見解
  • 市場吸引力分析

第 3 章：研究方法

第 4 章：流涎市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈供應商名單

第 5 章：流涎市場 - 主要市場動態

  • 主要市場促進因素
  • 主要市場限制
  • 主要市場機會
  • 未來的趨勢
  • 促進因素和限制因素的影響分析

第 6 章：流涎市場 - 全球市場分析

  • 流涎 - 全球市場概覽
  • 流涎 - 全球市場與 2030 年預測

第 7 章：流涎市場 - 收入分析 - 按藥物治療，2020-2030 年

  • 概述
  • 藥物治療
  • 放射治療
  • 其他

第 8 章：流涎市場 - 收入分析 - 按最終用戶，2020-2030 年

  • 概述
  • 醫院
  • 專科診所
  • 家庭護理設置
  • 其他

第 9 章：流涎市場 - 收入分析，2020-2030 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

註 - 將為以下提到的地區/國家提供類似的分析

  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 10 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 11 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與專注

第 12 章：流涎市場 - 主要公司概況

  • Supernus Pharmaceuticals, Inc.

注意 - 將為以下公司列表提供類似資訊

  • 普羅維卡有限公司
  • 梅爾茨製藥股份有限公司。
  • 艾爾建
  • 葛蘭素史克
  • 鹽野木公司
  • 拜耳公司
  • 諾華製藥公司
  • 諾貝爾製藥有限公司
  • 百時美施貴寶公司

第 13 章：附錄

  • 詞彙表
  • 關於 Insight Partners
  • 市場情報雲
簡介目錄
Product Code: TIPRE00033418

According to our latest study on "Sialorrhea Treatment Market Forecast to 2030 - Global Analysis - by Medical Therapy and End User," the market was valued at US$ 0.695 billion in 2022 and is expected to reach US$ 1.042 billion by 2030; it is estimated to record a CAGR of 5.2% from 2022 to 2030.

The market growth is attributed to the increasing prevalence of neurodegenerative disorders and the availability of various treatment options for sialorrhea. Moreover, rising research and development (R&D) and new drug approvals will likely fuel the sialorrhea treatment market growth in the coming years. However, challenges related to sialorrhea treatment restrain the market growth.

Treatments for sialorrhea include behavioral and lifestyle counseling, medication, surgery, and radiation. Nonpharmacological therapies include advice on posture, controlling swallowing, managing cough, dietary adjustments, eating and drinking procedures, and behavioral modification. Nevertheless, these conservative measures might not work for individuals with neurological problems that worsen over time. Many drugs that have been used to treat sialorrhea also have anticholinergic properties that have been utilized to control hypersalivation. Amitriptyline, procyclidine, and rihexyphenidyl are a few of these. Most medications have co-morbidities (such as discomfort or trouble sleeping) and hypersalivation, which makes them potentially helpful in some situations. Therefore, the availability of various treatments for sialorrhea is expected to boost market growth in the coming years.

However, diagnosis and treatment of chronic sialorrhea are delayed due to patient and healthcare professional ignorance about the condition. This is anticipated to be the main obstacle impeding the market expansion for chronic sialorrhea treatments. Furthermore, it is anticipated that healthcare professionals-including specialists and primary care doctors-will know very little about persistent sialorrhea as a separate illness.

The report segments the sialorrhea treatment market as follows:

The sialorrhea treatment market is bifurcated based on medical therapy and end users. The market is segmented by medical treatment into pharmacologic therapy, radiotherapy, and others. The sialorrhea treatment market, by end-user, is segmented into hospitals, specialty clinics, home care settings, and others. The sialorrhea treatment market, based on geography, is categorized into North America (the US, Canada, and Mexico), Europe (France, Germany, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America)

Medical Therapy-Based Insights

Based on medical therapy, the sialorrhea treatment market is segmented into pharmacologic therapy, radiotherapy, and others. In 2022, the pharmacologic therapy segment held the largest market share. Also, the segment is expected to record the highest CAGR from 2022 to 2030. Vaccines provide active acquired immunity against particular infectious diseases. In multiple independent clinical trials, pharmacological treatments such as benztropine, glycopyrrolate, scopolamine, and botulinum toxins have been demonstrated to be effective in managing sialorrhea. Medications are delivered orally or parenterally. Botulinum toxin is injected into the salivary gland guided by anatomical external palpation or ultrasonography.

End User-Based Insights

The sialorrhea treatment market, by end-user, is segmented into hospitals, specialty clinics, home care settings, and others. The hospitals segment held the largest market share in 2022 and is anticipated to record the highest CAGR during 2022-2030. The treatment for sialorrhea is done in hospitals through appropriate treatment and motor therapy, with the help of highly experienced interdisciplinary medical specialists, including physiotherapists and neurology specialists.

A few of the major primary and secondary sources referred to while preparing the report on the sialorrhea treatment market are the World Health Organization (WHO) and the Parkinson's Foundation, among others.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Sialorrhea Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Sialorrhea Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Sialorrhea Market - Global Market Analysis

  • 6.1 Sialorrhea - Global Market Overview
  • 6.2 Sialorrhea - Global Market and Forecast to 2030

7. Sialorrhea Market - Revenue Analysis (USD Million) - By Medical Therapy, 2020-2030

  • 7.1 Overview
  • 7.2 Pharmacologic Therapy
    • 7.2.1 Anticholinergic
    • 7.2.2 Botulinum Toxins
  • 7.3 Radiotherapy
  • 7.4 Others

8. Sialorrhea Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 8.1 Overview
  • 8.2 Hospitals
  • 8.3 Specialty Clinics
  • 8.4 Homecare Settings
  • 8.5 Others

9. Sialorrhea Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Sialorrhea Market Overview
    • 9.1.2 North America Sialorrhea Market Revenue and Forecasts to 2030
    • 9.1.3 North America Sialorrhea Market Revenue and Forecasts and Analysis - By Medical Therapy
    • 9.1.4 North America Sialorrhea Market Revenue and Forecasts and Analysis - By End User
    • 9.1.5 North America Sialorrhea Market Revenue and Forecasts and Analysis - By Countries
      • 9.1.5.1 United States Sialorrhea Market
        • 9.1.5.1.1 United States Sialorrhea Market, by Medical Therapy
        • 9.1.5.1.2 United States Sialorrhea Market, by End User
      • 9.1.5.2 Canada Sialorrhea Market
        • 9.1.5.2.1 Canada Sialorrhea Market, by Medical Therapy
        • 9.1.5.2.2 Canada Sialorrhea Market, by End User
      • 9.1.5.3 Mexico Sialorrhea Market
        • 9.1.5.3.1 Mexico Sialorrhea Market, by Medical Therapy
        • 9.1.5.3.2 Mexico Sialorrhea Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 France
    • 9.2.3 Italy
    • 9.2.4 Spain
    • 9.2.5 United Kingdom
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 Australia
    • 9.3.2 China
    • 9.3.3 India
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 Middle East and Africa
    • 9.4.1 South Africa
    • 9.4.2 Saudi Arabia
    • 9.4.3 U.A.E
    • 9.4.4 Rest of Middle East and Africa
  • 9.5 South and Central America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of South and Central America

10. Industry Landscape

  • 10.1 Mergers and Acquisitions
  • 10.2 Agreements, Collaborations, Joint Ventures
  • 10.3 New Product Launches
  • 10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Sialorrhea Market - Key Company Profiles

  • 12.1 Supernus Pharmaceuticals, Inc.
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 12.2 Proveca Ltd
  • 12.3 Merz Pharmaceuticals, LLC.
  • 12.4 Allergan
  • 12.5 GlaxoSmithKline
  • 12.6 Shionogi Inc.
  • 12.7 BAYER INC
  • 12.8 Novartis Pharmaceuticals Corporation
  • 12.9 Nobelpharma Co., Ltd.
  • 12.10 Bristol-Myers Squibb Company

13. Appendix

  • 13.1 Glossary
  • 13.2 About The Insight Partners
  • 13.3 Market Intelligence Cloud